Statement: Nobody in cohort 1 of the primary trial suffered from Hyperbilirrubinemia.
Primary_evidence: Adverse Events 1:   Total: 23/436 (5.28%)   Neutropenia G 3; Leucopenia G2 1/436 (0.23%)   Hyperbilirrubinemia  [1]1/436 (0.23%)   Supraventricular arrhythmia NOS  [2]1/436 (0.23%)   Heart failure  [2]0/436 (0.00%)   Infarction and cardiac arrest 0/436 (0.00%)   Ischemia cardiac/Infarction  [3]1/436 (0.23%)   Coronary vasospam  [3]1/436 (0.23%)   Gastroenteritis and renal insuficience 1/436 (0.23%) Adverse Events 2:   Total: 6/425 (1.41%)   Neutropenia G 3; Leucopenia G2 0/425 (0.00%)   Hyperbilirrubinemia  [1]0/425 (0.00%)   Supraventricular arrhythmia NOS  [2]0/425 (0.00%)   Heart failure  [2]1/425 (0.24%)   Infarction and cardiac arrest 1/425 (0.24%)   Ischemia cardiac/Infarction  [3]0/425 (0.00%)   Coronary vasospam  [3]0/425 (0.00%)   Gastroenteritis and renal insuficience 0/425 (0.00%)